Skip to Main Content

National Coverage Analysis (NCA) Tracking Sheet for Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R)

Positron emission tomography (PET) is a non-invasive imaging procedure used to assess metabolic activity in various organs or tissues in the human body. Images are obtained by processing emissions from positron-emitting radioisotopes that are usually administered intravenously. Sodium Fluoride F-18 (NaF-18) is a radioisotope used in PET imaging to detect bone metastasis of cancer.

Section 220.6 of the National Coverage Determination Manual identifies 2-[F18] fluoro-2-deoxy-D-glucose (FDG) as the only nationally covered radioisotope for use in PET for cancer imaging. CMS is reconsidering Section 220.6 of the NCD Manual to review evidence on the use of NaF-18 to identify bone metastasis of cancer.

Diagnostic Tests (other)
Requestor Name(s)Internally Generated
Formal Request Accepted and Review Initiated06/04/2009
Expected NCA Completion Date02/28/2010
Public Comment Period06/04/2009 - 07/04/2009
Proposed Decision Memo Released11/30/2009
Proposed Decision Memo Public Comment Period: 11/30/2009 - 12/30/2009 
Decision Memo Released02/26/2010
Comments for this NCA:View Public Comments
Lead Analyst(s)
Lead Medical Officer(s)
  • Jeffrey Roche, MD, MPH

June 4, 2009

CMS opens this reconsideration of Section 220.6 of the NCD on Positron Emission Tomography (PET) to review evidence on the use of NaF-18 to identify bone metastasis of cancer. The initial 30-day public comment period begins with this posting date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in clinical studies and other scientific information relevant to the technology under review.

Instructions on submitting comments can be found at: http://www.cms.hhs.gov/InfoExchange/02_publiccomments.asp#TopOfPage.

To submit a comment, please use the orange "COMMENT" button at the top of the page.

November 30, 2009

CMS posts the Proposed Decision Memorandum. The 30-day public comment period on the proposed decision begins with this posting date, and ends after 30 calendar days. CMS considers all public comments, and is particularly interested in new evidence relevant to the technology under review.

Instructions on submitting comments can be found at: http://www.cms.hhs.gov/InfoExchange/02_publiccomments.asp#TopOfPage.

To submit a comment, please use the orange "COMMENT" button at the top of the page.

February 26, 2010

78